No­vo Nordisk pe­ti­tions FDA to stop semaglu­tide com­pound­ing over safe­ty risks

No­vo Nordisk is con­tin­u­ing its cru­sade against com­pound­ed ver­sions of its block­buster weight loss drugs by pe­ti­tion­ing the FDA to stop al­low­ing such wide­spread man­u­fac­tur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER